Announcement of AGM (1873W)
26 January 2012 - 5:00AM
UK Regulatory
TIDMMEDG TIDMMEDU
RNS Number : 1873W
Medgenics Inc
25 January 2012
Press Release 25 January 2012
Medgenics Sets Record Date for 2012 Annual Meeting of
Stockholders
Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the
"Company"), the developer of a novel technology for the sustained
production and delivery of therapeutic proteins in patients using
their own tissue, today announced that its Board of Directors has
set the close of business on March 2, 2012 (5:00 p.m., PST) as the
record date for stockholders entitled to vote at the Company's 2012
Annual Meeting of Stockholders. The Company will hold its Annual
Meeting on April 3, 2012 at the offices of Duane Morris LLP located
at 1540 Broadway, New York, New York (or such other time and
location as may be determined by the Chairman or Chief Executive
Officer of the Company).
In addition, the Company wishes to inform stockholders that the
deadline for submitting a timely stockholder proposal for potential
inclusion in the proxy statement for the 2012 Annual Meeting of
Stockholders has been set at February 24, 2012. In order for a
stockholder proposal to be considered for inclusion in the proxy
statement, it must be received by the Company on or prior to the
close of business on February 24, 2012 (5:00 p.m., PST) at its
principal executive offices at 555 California Street, Suite 365,
San Francisco, California 94104. Notices of stockholder proposals
or director nominations intended to be presented at the 2012 Annual
Meeting must also be received on or prior to the close of business
on February 24, 2012 (5:00 p.m., PST) at the same address. These
notices and stockholder proposals should be sent to the attention
of Eugene A. Bauer, M.D., Executive Chairman of the Board.
The Company plans to file a proxy statement in connection with
the 2012 Annual Meeting of Stockholders with the Securities and
Exchange Commission (SEC). When completed, the proxy statement and
the Company's Annual Report on Form 10-K for the year ended
December 31, 2011 will be sent to stockholders of record and will
also be available on the SEC's website at www.sec.gov and on the
Company's website at www.medgenics.com.
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own skin biopsy for the treatment of a range of chronic diseases
including anemia, hepatitis C and hemophilia. Medgenics believes
this approach has multiple benefits compared with current
treatments, which include regular and costly injections of
therapeutic proteins.
Medgenics has three long-acting protein therapy products in
development based on this technology:
-- EPODURE (now completing a Phase I/II dose-ranging trial) to
produce and deliver erythropoietin for many months from a single
administration, has demonstrated elevation and stabilization of
hemoglobin levels in anemic patients for six to more than 36
months;
-- INFRADURE (planning to commence a Phase I/II trial in Israel
in 1H12 in hepatitis C) to produce a sustained therapeutic dose of
interferon-alpha for use in the treatment of hepatitis;
-- HEMODURE is a sustained Factor VIII therapy for the
prophylactic treatment of hemophilia, now in development.
Medgenics intends to develop its innovative products and bring
them to market via strategic partnerships with major pharmaceutical
and/or medical device companies.
In addition to treatments for anemia, hepatitis and hemophilia,
Medgenics plans to develop and/or out-license a pipeline of future
Biopump(TM) products targeting the large and rapidly growing global
protein therapy market, which is forecast to reach $132 billion in
2013. Other potential applications for Biopumps(TM) include
multiple sclerosis, arthritis, pediatric growth hormone deficiency,
obesity and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
Andrew.pearlman@medgenics.com
LHA Phone: 212-838-3777
Anne Marie Fields
afields@lhai.com
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
Religare Capital Markets (NOMAD) Phone: +44 207 444 0800
Emily Staples
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Mattey
Ian Callaway
Nomura Code Securities (Joint Broker) Phone: +44 207 776 1219
Jonathan Senior
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBKPDBABKDCDB
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Oct 2024 to Nov 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Nov 2023 to Nov 2024
